Rucaparib maintenance therapy provided consistent benefits across all subgroups of patients grouped by prognostic factors of their homologous recombination deficiency-negative ovarian cancer tumors.
MIAMI, FL / ACCESS Newswire / October 9, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir” or the “Company”), a preclinical-stage biotechnology company developing therapies that target ...
Goto et al. 1 recently described a novel mechanism of immune evasion during the initial steps in the development of colorectal cancer in which nascent cancer cells reactivate a fetal program that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results